A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers
Latest Information Update: 05 Jul 2024
At a glance
- Drugs DWP 17061 (Primary)
- Indications Postherpetic neuralgia
- Focus Adverse reactions
- Sponsors iN Therapeutics
- 05 Jul 2024 Last checked against ClinicalTrials.gov record.
- 24 Jun 2024 Planned End Date changed from 8 Feb 2024 to 29 Jul 2024.
- 24 Jun 2024 Planned primary completion date changed from 8 Feb 2024 to 29 Jul 2024.